Premium
Trimetazidine does not modify blood levels and immunosuppressant effects of cyclosporine A in renal allograft recipients
Author(s) -
Simon Nicolas,
Brunet Philippe,
Roumenov Dimitri,
Dussol Bertrand,
Barre Jerome,
Duche JeanClaude,
Albengres Edith,
D’Athis Philippe,
ChauvetMonges AnneMarie,
Berland Yvon,
Tillement JeanPaul
Publication year - 1997
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.1997.t01-1-00628.x
Subject(s) - trimetazidine , medicine , pharmacology , nephrotoxicity , pharmacokinetics , creatinine , kidney , urology
Aims In renal allograft recipients, trimetazidine (Vastarel ® ) was proposed to be associated with the classic immunosuppressant treatments because it displays anti‐ischaemic effects which may protect against cyclosporine A nephrotoxicity. The objective of this work was to assess the possibility of coadministering cyclosporin A, Sandimmun ® , and trimetazidine. Methods Twelve renal transplant patients were selected on the basis of the stability of their cyclosporine A blood concentrations for the previous 3 months. They received trimetazidine, 40 mg twice daily orally for 5 days. Other coadministered drugs were kept unchanged during the study. Before and after trimetazidine administration, cyclosporine A blood concentrations, plasma interleukin‐2 and soluble interleukin‐2 receptor levels were measured. Results The data showed that neither cyclosporin A blood pharmacokinetic parameters, C max , t max , AUC, nor the concentrations of interleukin‐2 and soluble interleukin‐2 receptors were significantly modified. Conclusions Therefore, it was suggested that trimetazidine may be coadministered with cyclosporine A without cyclosporine A dosage adjustment.